Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors
Status:
Recruiting
Trial end date:
2024-12-01
Target enrollment:
Participant gender:
Summary
A prospective, open-label, multi-cohort, non-randomized, multicenter Phase 2 study evaluating
adoptive cell therapy (ACT) with TIL LN-144 (Lifileucel)/LN-145 in combination with
checkpoint inhibitors or TIL LN-144 (Lifileucel)/LN-145/LN-145-S1 as a single agent therapy.